File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: A 6-month prospective pilot study

TitlePhacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: A 6-month prospective pilot study
Authors
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eye
Citation
Eye, 2005, v. 19 n. 8, p. 885-890 How to Cite?
AbstractAims: To assess the safety and efficacy of phacoemulsification with intravitreal triamcinolone (ivTA) injection in diabetics with cataract and clinically significant macular oedema (CSMO). Methods: A total of 19 eyes of 15 consecutive diabetic patients with cataract and CSMO were prospectively recruited. Patients underwent phacoemulsification and intraocular lens implantation with 4 mg ivTA injection at completion of surgery. Patients were followed up on day 1, then weekly for 1 month, and thereafter monthly until 6 months postoperatively. Best corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography, and adverse events were recorded. Results: In total, 17 eyes completed 6 months of follow-up. In all, 58.8% showed improvement in BCVA of ≥2 lines, with statistically significant improvement in mean Snellen BCVA of 2.4 lines at 6 months. The peak BCVA was achieved at 4 months. The mean CMT decreased from a baseline of 449 pm to a minimum of 321 ± 148 μm (28.5% reduction) achieved at 2 months, with statistically significant reduction at all postoperative time intervals until 6 months. Of 17 eyes, 4 (23.5%) developed transiently elevated intraocular pressure that normalised by 6 months in all but one patient. No injection- or surgery-related complications were encountered. Conclusions: Phacoemulsification with concurrent 4 mg ivTA injection appears to be a safe option for managing diabetics with cataract and CSMO. However, large-scaled randomised controlled trials are necessary for delineating the relative contributions of cataract removal and CMT reduction to visual improvement. Moreover, the transient effect on CMT may warrant further studies to determine optimal timing and dosage of further ivTA injections. © 2005 Nature Publishing Group All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/176426
ISSN
2015 Impact Factor: 2.213
2015 SCImago Journal Rankings: 1.132
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, DSCen_US
dc.contributor.authorChan, CKMen_US
dc.contributor.authorMohamed, Sen_US
dc.contributor.authorLai, TYYen_US
dc.contributor.authorLee, VYWen_US
dc.contributor.authorLai, WWen_US
dc.contributor.authorFan, DSPen_US
dc.contributor.authorChan, WMen_US
dc.date.accessioned2012-11-26T09:11:12Z-
dc.date.available2012-11-26T09:11:12Z-
dc.date.issued2005en_US
dc.identifier.citationEye, 2005, v. 19 n. 8, p. 885-890en_US
dc.identifier.issn0950-222Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/176426-
dc.description.abstractAims: To assess the safety and efficacy of phacoemulsification with intravitreal triamcinolone (ivTA) injection in diabetics with cataract and clinically significant macular oedema (CSMO). Methods: A total of 19 eyes of 15 consecutive diabetic patients with cataract and CSMO were prospectively recruited. Patients underwent phacoemulsification and intraocular lens implantation with 4 mg ivTA injection at completion of surgery. Patients were followed up on day 1, then weekly for 1 month, and thereafter monthly until 6 months postoperatively. Best corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography, and adverse events were recorded. Results: In total, 17 eyes completed 6 months of follow-up. In all, 58.8% showed improvement in BCVA of ≥2 lines, with statistically significant improvement in mean Snellen BCVA of 2.4 lines at 6 months. The peak BCVA was achieved at 4 months. The mean CMT decreased from a baseline of 449 pm to a minimum of 321 ± 148 μm (28.5% reduction) achieved at 2 months, with statistically significant reduction at all postoperative time intervals until 6 months. Of 17 eyes, 4 (23.5%) developed transiently elevated intraocular pressure that normalised by 6 months in all but one patient. No injection- or surgery-related complications were encountered. Conclusions: Phacoemulsification with concurrent 4 mg ivTA injection appears to be a safe option for managing diabetics with cataract and CSMO. However, large-scaled randomised controlled trials are necessary for delineating the relative contributions of cataract removal and CMT reduction to visual improvement. Moreover, the transient effect on CMT may warrant further studies to determine optimal timing and dosage of further ivTA injections. © 2005 Nature Publishing Group All rights reserved.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eyeen_US
dc.relation.ispartofEyeen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAnti-Inflammatory Agents - Therapeutic Useen_US
dc.subject.meshCataract - Complicationsen_US
dc.subject.meshDiabetic Retinopathy - Complicationsen_US
dc.subject.meshEpidemiologic Methodsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlucocorticoids - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMacular Edema - Complications - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPhacoemulsification - Adverse Effects - Methodsen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTriamcinolone Acetonide - Therapeutic Useen_US
dc.subject.meshVisual Acuityen_US
dc.titlePhacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: A 6-month prospective pilot studyen_US
dc.typeArticleen_US
dc.identifier.emailLai, WW: wicolai@hku.hken_US
dc.identifier.authorityLai, WW=rp00531en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/sj.eye.6701686en_US
dc.identifier.pmid15389275-
dc.identifier.scopuseid_2-s2.0-23944457629en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23944457629&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume19en_US
dc.identifier.issue8en_US
dc.identifier.spage885en_US
dc.identifier.epage890en_US
dc.identifier.isiWOS:000231019800011-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLam, DSC=35500200200en_US
dc.identifier.scopusauthoridChan, CKM=7404813824en_US
dc.identifier.scopusauthoridMohamed, S=23477897700en_US
dc.identifier.scopusauthoridLai, TYY=7202203581en_US
dc.identifier.scopusauthoridLee, VYW=8078995500en_US
dc.identifier.scopusauthoridLai, WW=7402231098en_US
dc.identifier.scopusauthoridFan, DSP=7202965663en_US
dc.identifier.scopusauthoridChan, WM=7403914485en_US
dc.identifier.citeulike241808-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats